BPC 157 for Gut Healing: A Functional Medicine Protocol

Most FM practitioners run comprehensive gut healing protocols — elimination diet, probiotics, L-glutamine, zinc carnosine. You've done the foundational work. The patients who plateau there are who this article is for.

BPC 157 is what you reach for when those protocols have stalled or need acceleration. It's not a replacement for the 5R framework — it's a powerful adjunct in the Repair phase when the usual tools aren't getting you across the finish line.

Why BPC 157 for the Gut?

BPC 157 is a partial sequence of gastric BPC — the body already produces this compound to protect the gut lining. Supplemental BPC 157 amplifies an endogenous signal, not introducing something foreign. That's the key context for the safety profile.

Tight junction upregulation. BPC 157 increases expression of claudin-1, occludin, and ZO-1 — the proteins that form the architectural structure of the intestinal barrier. This directly repairs leaky gut architecture [PMID: 32445447].

Mucosal angiogenesis. BPC 157 drives new capillary formation in the damaged mucosal layer. This brings blood supply to areas that are avascular or ischemic — critical for healing chronic mucosal damage.

Enterocyte proliferation and migration. BPC 157 accelerates villus regeneration and reduces crypt atrophy. The gut lining turns over every 3-5 days; BPC 157 pushes that regeneration faster.

Anti-inflammatory at the epithelial level. BPC 157 reduces COX-2, prostaglandin E2, and IL-1β in intestinal epithelial cells without the systemic immunosuppression risks of pharmaceuticals.

Gut-brain axis modulation. BPC 157 interacts with dopamine and serotonin systems via vagal pathways. This may contribute to motility normalization and the gut-brain symptoms in functional gut disorders.

Why does oral work? High first-pass metabolism means BPC 157 concentrates in the gut lumen and mucosa before systemic clearance. This is mechanistically ideal — the compound reaches the tissue that needs healing at therapeutic concentrations.

Indications

Intestinal hyperpermeability (leaky gut). Primary indication. Direct mechanism (tight junction repair, VEGF-driven mucosal angiogenesis). Best results when gut microbiome dysbiosis is also being addressed concurrently. Expect zonulin reduction and lactulose:mannitol normalization as objective outcomes. Timeline: 8–12 weeks for measurable improvement.

Inflammatory bowel disease (Crohn's, ulcerative colitis). Mucosal healing adjunct — not a replacement for immunosuppressive therapy in active moderate-severe IBD. Best position: maintenance phase or mild disease; complements 5-ASA agents and LDN. Animal model data on IBD healing is robust; human data is emerging. KPV as a combination partner (melanocortin receptor agonism) creates a dual-pronged gut anti-inflammatory approach.

SIBO recovery — post-antimicrobial mucosal repair. Often overlooked. Successful SIBO eradication (rifaximin, herbal protocols) leaves damaged intestinal mucosa that delays the Reinoculate and Repair phases. BPC 157 oral × 8 weeks post-antibiotic dramatically accelerates mucosal restoration. This is where I see the most dramatic results — patients who've done three rounds of SIBO treatment and still have residual symptoms finally get resolution when you add BPC 157 to the Repair phase.

NSAID-induced GI damage. Gastroprotective and reversal properties in animal models. Clinical scenario: patient on chronic NSAIDs transitioning to peptide protocols — gut repair concurrent with musculoskeletal healing.

Post-infectious enteropathy. Post-COVID GI syndrome, post-Giardia, post-Cryptosporidium mucosal repair.

Protocol: Step-by-Step

Step 1: Confirm Indication and Baseline

Document:

• Current gut symptoms (standardized questionnaire — GSRS or similar)
• Objective baseline markers:
  • Zonulin (serum) — tight junction permeability
  • Lactulose:mannitol ratio — intestinal permeability
  • hs-CRP — systemic inflammatory load
  • CBC, CMP — general health
  • Calprotectin (if IBD suspected)
  • Secretory IgA (if available)
• Current gut protocol: what's already in place (elimination diet, probiotics, L-glutamine, zinc carnosine, etc.)

Step 2: Sourcing and Quality Verification

Verify:

• Compounding pharmacy is 503A or 503B
• Certificate of Analysis (COA) available for batch
• Peptide purity ≥99%
• Sterility testing documented
• Endotoxin testing documented

If a patient has self-sourced from a research supplier, document that you reviewed their COA and source, and that they have signed informed consent acknowledging research-use status.

Step 3: Dosing Protocol

Standard oral BPC 157 gut healing:

• Dose: 500 mcg oral, twice daily (AM and PM)
• Duration: 8–12 weeks
• Timing: Take on empty stomach, 30 minutes before meals

Enhancement protocol (severe leaky gut or IBD):

• Dose: 500 mcg oral, three times daily (some practitioners use this for 4 weeks then step down to twice daily)
• Duration: 12 weeks
• Monitor for GI tolerance issues

Combination protocol (leaky gut + tendinopathy):

• Oral BPC 157 500 mcg BID (gut)
• SubQ BPC 157 250–500 mcg daily (musculoskeletal)
• Duration: 10–12 weeks
• Addresses both systems concurrently

Step 4: Integration with 5R Protocol

BPC 157 does not replace the 5R framework. It accelerates the Repair phase.

Remove: Continue dietary removals (gluten, dairy, etc.) as indicated Replace: Continue digestive support (HCl, enzymes, bile acids) as indicated
Reinoculate: Continue probiotics and prebiotics Repair: This is where BPC 157 fits — as an advanced Repair tool alongside L-glutamine, zinc carnosine, colostrum, and mucosal support nutrients Rebalance: Continue stress management, sleep optimization

BPC 157 is not a standalone intervention. It amplifies repair that is already happening when the foundational 5R work is in place.

Step 5: Monitoring Schedule

Week 0 (Baseline):

• Symptom questionnaire
• Labs: zonulin, lactulose:mannitol, hs-CRP, CBC, CMP

Week 4:

• Symptom reassessment
• Clinical observation: any GI tolerance issues?

Week 8–10:

• Symptom reassessment
• Repeat zonulin and hs-CRP
• This is where you expect to see measurable improvement

Week 12 (Cycle End):

• Full reassessment
• Labs: zonulin, lactulose:mannitol, hs-CRP
• Decision: hold, cycle off, or continue (most protocols cycle off at 12 weeks)

Step 6: Post-Protocol Assessment

Evaluate:

• Did zonulin normalize or improve?
• Did lactulose:mannitol ratio improve?
• Did hs-CRP decrease?
• Did symptoms improve on the standardized questionnaire?
• Is the patient ready to maintain without BPC 157?

Most patients cycle off at 12 weeks and maintain with the foundational 5R protocol. Some patients with chronic conditions (Crohn's maintenance, long-standing leaky gut) may need repeat cycles.

Expected Outcomes

Timeline:

• Weeks 2–4: Some symptom improvement (bloating reduction, better stool consistency)
• Weeks 8–10: Measurable improvement in objective markers (zonulin reduction, hs-CRP decrease)
• Weeks 10–12: Consolidation of gains

Realistic outcomes:

• Leaky gut (zonulin elevated): Expect 40–60% zonulin reduction, symptom improvement
• IBD maintenance: Expect mucosal healing support, reduced flare frequency (anecdotal, not RCT data)
• Post-SIBO repair: Expect normalization of permeability markers

What to manage expectations about:

• BPC 157 is not a cure for autoimmune IBD
• Results depend on adherence to the foundational 5R protocol
• If dysbiosis is not addressed concurrently, benefits may not hold

BPC 157 vs. KPV

Both are gut-healing peptides, but mechanisms differ:

Factor	BPC 157	KPV
Mechanism	VEGF/angiogenesis, tight junction, GH sensitization	Melanocortin receptor (MC1R/MC3R) agonism
Primary use	Leaky gut, mucosal repair, tendinopathy (systemic)	IBD, gut-specific inflammation
Evidence base	More animal data, broader indications	Strong IBD-specific data, more targeted
Best for	Multi-system healing (gut + musculoskeletal)	Pure gut inflammation (IBD, colitis)

My clinical approach: Use BPC 157 for leaky gut and general gut repair. Use KPV for IBD-specific inflammation. Consider stacking both for severe IBD or for patients who've plateaued on BPC 157 alone.

KPV (Lys-Pro-Val) is a C-terminal fragment of alpha-MSH that binds melanocortin receptors in the gut epithelium. It reduces NF-κB and TNF-α in intestinal epithelial cells with no systemic hormone-like effects [PMID: 18092346]. It's underutilized in FM practice, probably because it's less well-known than BPC 157. But for the right patient, it's powerful.

FAQ

Does oral BPC 157 actually work, or does it need to be injected? For gut healing specifically, oral works. Limited systemic absorption is the mechanism — it concentrates in the gut lumen where it can repair the mucosal barrier. Injectable is needed for systemic or musculoskeletal effects.

How long does a gut healing protocol take? 8–12 weeks for measurable improvement. Most patients cycle off at 12 weeks and maintain with foundational protocol.

What GI biomarkers should I track? Zonulin (serum), lactulose:mannitol ratio, hs-CRP. Calprotectin if IBD is the indication. Repeat at week 8–10.

Can I combine BPC 157 with other gut healing supplements? Yes — BPC 157 complements L-glutamine, zinc carnosine, colostrum, and mucosal support nutrients. It does not replace them.

What if my patient has already self-sourced BPC 157? Document that you reviewed their source and COA. Document informed consent. Continue to monitor labs and symptoms. Do not prescribe research chemicals.

---

Cross-link: For the complete FM peptide therapy framework, see Peptide Therapy Protocols: A Functional Medicine Practitioner's Guide. For anti-inflammatory peptides beyond BPC 157, see Peptides for Inflammation: What FM Practitioners Need to Know.

---

Ready to streamline gut healing protocol documentation? See HANS pricing and features — pre-built 5R protocol templates, BPC 157 monitoring workflows, and automated zonulin tracking built in.